title: Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study.
abstract: OBJECTIVE
  Analysis and evaluation of a multidisciplinary approach, postoperative results and survival of a group of patients with resected pancreatic cancer after a multimodal therapy.
  
  
  METHODS
  DESCRIPTIVE, prospective and observational study.
  
  
  METHODS
  Between January 2004 and December 2004, 124 patients with pancreatic cancer were evaluated. In 30 patients pancreatic resection was performed, and they are the object of this study. Results of preoperative evaluation, postoperative morbidity and mortality, and long term survival were studied.
  
  
  RESULTS
  Diagnostic evaluation was completed in ambulatory basis in 20% of the patients. In 63% of cases, admission was done in the same day of surgery. In 3 patients (9%), tumor resection was not achieved, therefore, concordance between radiological and surgical resectability rate was 91%. Resectability rate was 24.1%. Surgical Mortality was 3.3%, with a global morbidity rate of 56.6%. Survival at one, two, three and, four years was 76.2%, 56.3%, 43%, y 27.3% respectively.
  
  
  CONCLUSIONS
  Technological development and coordination of efforts in multidisciplinary teams offer an accurate evaluation of tumor involvement, and may reduce the number of laparotomies without tumor resection. The application of a systematic and generalized multimodal treatment in pancreatic cancer is progressively showing a tendency of progressive increase in resectability and survival rates in pancreatic cancer.
authors.affiliation: Department of Surgery, Hospital Son Llátzer. Palma de Mallorca, Spain. rafa.morales@telefonica.es
authors.forename: R
authors.initials: R
authors.lastname: Morales
authors.forename: A
authors.initials: A
authors.lastname: Cuadrado
authors.forename: J F
authors.initials: JF
authors.lastname: Noguera
authors.forename: C
authors.initials: C
authors.lastname: Dolz
authors.forename: A
authors.initials: A
authors.lastname: Vilella
authors.forename: J
authors.initials: J
authors.lastname: Riera
authors.forename: M
authors.initials: M
authors.lastname: González de Cabo
authors.forename: A
authors.initials: A
authors.lastname: Arriví
authors.forename: E
authors.initials: E
authors.lastname: Falcó
authors.forename: M
authors.initials: M
authors.lastname: García Bonafe
authors.forename: M
authors.initials: M
authors.lastname: Company
authors.forename: J C
authors.initials: JC
authors.lastname: Vicens
authors.forename: A
authors.initials: A
authors.lastname: Socías
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002760:Cholangiopancreatography, Endoscopic Retrograde; D003082:Colectomy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003952:Diagnostic Imaging; D005260:Female; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010180:Pancreatectomy / Q000379:methods* / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D010348:Patient Care Team; D011446:Prospective Studies; D015607:Stents; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine